ArticleNeuroImage. Clinical2019
Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging.
Article in NeuroImage. Clinical, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Ultra-High-Field MRI in the Diagnosis and Management of Gliomas: A Systematic Review.Frontiers in neurology · 2022Pooled it
- 5T-Based Glutamate Chemical Exchange Saturation Transfer Imaging for Adult Diffuse Glioma Stratification.Journal of magnetic resonance imaging : JMRI · 2026Article
- Ultra-high-field 7-Tesla MRI in neuro-oncology: a narrative review of current applications and future directions.Quantitative imaging in medicine and surgery · 2026Review
- Transformer Enabled Half Z‑spectrum Sampling BChemical & biomedical imaging · 2026Article
- CEST MRI reveals nicotine-induced alterations in glutamate-associated molecular connectivity in the mouse brain.Frontiers in neuroscience · 2026Article
- CEST MRI assessment of HIV-1-associated neurometabolic impairments in a humanized mouse model.NeuroImmune pharmacology and therapeutics · 2025Article
- 5T chemical exchange saturation transfer imaging improves glioma grading and genotyping prediction: a supplement to 3T diffusion and perfusion MRI.Journal of translational medicine · 2025Article
- Measurement of Glutamate Suppression in a 6-OHDA-Induced Dopamine Deficiency Rat Model Following Acute Single-Dose L-DOPA Using GluCEST/MRS.Biomedicines · 2025Article
- Quantitative molecular imaging using deep magnetic resonance fingerprinting.Nature protocols · 2025Review
- 7T GluCEST in Discriminating Gliomas with Diverse Invasiveness Degrees and Its Association with Invasion Indices.ACS chemical neuroscience · 2025Article
- The excitatory milieu in glioma: Mechanisms and therapeutic avenues.Neuro-oncology · 2025Review
- Optimized Long-TEJournal of magnetic resonance imaging : JMRI · 2025Article
- Imaging the uptake and metabolism of glutamine in prostate tumor models using CEST MRI.Npj imaging · 2025Article
- Preclinical monitoring of radiation-induced brain injury via GluCEST MRI and resting-state fMRI at 7 T: an exploratory study on MRI-guided OAR avoidance.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Toward quantitative CEST imaging of glutamate in the mouse brain using a multi-pool exchange model calibrated byMagnetic resonance in medicine · 2025Article
- Clinical 7 Tesla magnetic resonance imaging: Impact and patient value in neurological disorders.Journal of internal medicine · 2025Review
- Application of 5T glutamate chemical exchange saturation transfer imaging in brain tumors: preliminary results.Journal of neuro-oncology · 2024Article
- 7 Tesla magnetic resonance spectroscopic imaging predicting IDH status and glioma grading.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.CNS neuroscience & therapeutics · 2024Review
- Implementation of a 7T Epilepsy Task Force consensus imaging protocol for routine presurgical epilepsy work-up: effect on diagnostic yield and lesion delineation.Journal of neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
introductionDiffuse gliomas are incurable malignancies, which undergo inevitable progression and are associated with seizure in 50-90% of cases. Glutamate has the potential to be an important glioma biomarker of survival and local epileptogenicity if it can be accurately quantified noninvasively.
methodsWe applied the glutamate-weighted imaging method GluCEST (glutamate chemical exchange saturation transfer) and single voxel MRS (magnetic resonance spectroscopy) at 7 Telsa (7 T) to patients with gliomas. GluCEST contrast and MRS metabolite concentrations were quantified within the tumour region and peritumoural rim. Clinical variables of tumour aggressiveness (prior adjuvant therapy and previous radiological progression) and epilepsy (any prior seizures, seizure in last month and drug refractory epilepsy) were correlated with respective glutamate concentrations. Images were separated into post-hoc determined patterns and clinical variables were compared across patterns.
resultsTen adult patients with a histo-molecular (n = 9) or radiological (n = 1) diagnosis of grade II-III diffuse glioma were recruited, 40.3 +/- 12.3 years. Increased tumour GluCEST contrast was associated with prior adjuvant therapy (p = .001), and increased peritumoural GluCEST contrast was associated with both recent seizures (p = .038) and drug refractory epilepsy (p = .029). We distinguished two unique GluCEST contrast patterns with distinct clinical and radiological features. MRS glutamate correlated with GluCEST contrast within the peritumoural voxel (R = 0.89, p = .003) and a positive trend existed in the tumour voxel (R = 0.65, p = .113).
conclusionThis study supports the role of glutamate in diffuse glioma biology. It further implicates elevated peritumoural glutamate in epileptogenesis and altered tumour glutamate homeostasis in glioma aggressiveness. Given the ability to non-invasively visualise and quantify glutamate, our findings raise the prospect of 7 T GluCEST selecting patients for individualised therapies directed at the glutamate pathway. Larger studies with prospective follow-up are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.